SH
Samit Hirawat (EVP,Chief Med.Offr.,Drug Dev.) filed 2 Form 4 reports in the past 24 months (2 purchases, 0 sales), most often in Bristol-Myers Squibb Company (BMY). Across 2 priced purchase filings, the average 21-session return was +1.5% from execution and +3.8% from disclosure (delay-adjusted; derived). The largest single filing was $202K of BMY (4,250 sh × $47.58, as filed), executed Apr 25 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+1.5%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+3.8%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$302K
shares × price, as filed
Last traded
Apr 25 2025
Filed Apr 29 2025
Median ADV $761.0M across their filed names
Open performance→Volume by month
Buys $302K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 24 months
Most traded names
BMYRecent filings
BMYPURCHASE
Bristol-Myers Squibb Company
View filing →
$202K4,250 sh × $47.58
Exec Apr 25 2025
Filed Apr 29 2025 · 5:30 PM ET BMYPURCHASE Bristol-Myers Squibb Company View filing → $100K
1,823 sh × $54.84
Exec Feb 14 2025
Filed Feb 19 2025 · 5:30 PM ET BMYPURCHASE Bristol-Myers Squibb Company View filing → $100K
1,830 sh × $54.68
Exec Nov 1 2024
Filed Nov 5 2024 · 5:30 PM ET